BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp. BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW; TSX: BCT) is developing therapies to destroy cancer

12/25/2025

From everyone at BriaCell, wishing you and your family a happy, healthy holiday season filled with joy and special moments!

12/23/2025

ICYMI: BriaCell’s Phase 3 clinical trial in metastatic breast cancer featured as “clinical trial to watch in 2026” by Nature Medicine. Find the publication here: https://go.nature.com/3KDlDXt

12/19/2025

Dr. Sara A. Hurvitz, who holds the Smith Family Endowed Chair in Women’s Health at the Fred Hutchinson Cancer Center in Seattle, Washington, comments on BriaCell’s Phase 3 clinical trial in metastatic breast cancer, recently featured in Nature Medicine. https://bit.ly/48M8epf

12/18/2025

BriaCell (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) is pleased to announce its Phase 3 Bria-IMT™ clinical trial in metastatic breast cancer has been prominently and independently featured in the Nature Medicine Year In Review’s publication, “Eleven clinical trials that will shape medicine in 2026”. Find details: https://bit.ly/48M8epf

12/17/2025

“The pace of patient enrollment in our pivotal Phase 3 study has exceeded expectations underscoring the strong engagement of participating sites and the high level of interest from patients and investigators,” stated Dr. William V. Williams, BriaCell’s President & CEO. Learn more: https://bit.ly/3Mmv2mJ

12/15/2025

Miguel A. Lopez-Lago, PhD, BriaCell’s Chief Scientific Officer comments on the Company's positive clinical data presented in three posters at : https://bit.ly/3KSJxhy

12/11/2025

“BriaCell’s data shows the promise of the Bria-IMT regimen to address major unmet needs in the treatment of metastatic breast cancer, including in patients with CNS metastasis who have progressed on several lines of therapy – median 6 prior treatments,” stated Chaitali S. Nangia, MD, Partner, Hoag Medical Group and first author of the poster. https://bit.ly/3KSJxhy

12/10/2025

“We are very excited to see the robust and positive biomarker data, which may enable us to more confidently predict clinical responses in patients treated with the Bria-IMT regimen early in their treatment course,” stated Kelly E. McCann, MD, PhD, breast medical oncologist at UCLA Health Jonsson Comprehensive Cancer Center. Learn more: https://bit.ly/3KSJxhy

12/10/2025

BriaCell (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) presents positive Phase 2 survival, and Phase 3 biomarker data across three clinical posters at the 2025 San Antonio Breast Cancer Symposium (SABCS®) taking place December 9-12, 2025. Find details: https://bit.ly/3KSJxhy

12/09/2025

BriaCell's three poster presentations at the San Antonio Breast Cancer Symposium ( ), now available and to be presented on December 10, 2025, highlight robust survival and clinical benefit data in Phase 2, plus positive key biomarker data from the pivotal Phase 3 study. Learn more: https://bit.ly/48LbRvn

12/09/2025

BriaCell (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) is pleased to announce its Phase 3 clinical study has screened over 230 and enrolled over 160 patients. BriaCell anticipates reporting topline data as early as H12026. Find details: https://bit.ly/3Mmv2mJ

12/04/2025

“We are extremely pleased with biomarker and patient subgroup data suggesting their use for identifying patients who are most likely to benefit from our treatment,” stated Dr. Giuseppe Del Priore, BriaCell’s Chief Medical Officer. To learn more about the data being presented at , visit: https://bit.ly/48LbRvn

Address

2929 Arch Street, 3rd Floor
Philadelphia, PA
19104

Telephone

+18884856340

Website

Alerts

Be the first to know and let us send you an email when BriaCell Therapeutics Corp. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to BriaCell Therapeutics Corp.:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

BriaCell Therapeutics

Dedicated to enhance the lives of cancer patients who are facing limited therapeutic options, BriaCell Therapeutics Corp. (OTCQB: BCTXF; TSX: BCT.V)’s mission has been to develop novel immunotherapies, as the most cutting edge technology to fight cancer. Immunotherapies have become the forefront of the cancer treatments because they use the body’s immune system to destroy the cancer cells, offering higher levels of safety and efficacy than chemotherapy, with less likeliness of recurrence.

Designed by our team of scientists and clinicians, BriaCell’s proprietary whole-cell based technology platform continues to show its impressive potential to establish a new model for treating cancer patients. Our lead product candidate, Bria-IMT™ (SV-BR-1-GM), is a genetically engineered whole-cell based product candidate derived from a human breast cancer cell line. Bria-IMT™ is used in combination with multiple immune-modulators to powerfully trigger the immune system to recognize and eliminate cancerous cells.